Immunoglobulin heavy variable 4-34 B-cell receptor (IGHV4-34 BCR)

The Immunoglobulin heavy variable 4-34 (IGHV4-34) B-cell receptor is a clonotypic receptor encoded by a specific human germline gene segment that possesses inherent self-reactivity toward I/i carbohydrate antigens found on red blood cells and other tissues [8, 16, 18]. In healthy individuals, B cells expressing this receptor are strictly regulated and typically maintained in a state of clonal anergy, representing approximately 5% to 10% of the normal B-cell repertoire [1, 3, 20]. Pathologically, the IGHV4-34 BCR is the primary driver of Cold Agglutinin Disease (CAD), where it accounts for more than 85% of the pathogenic IgM autoantibodies responsible for complement-mediated hemolysis [9, 11, 12]. It also plays a significant role in Systemic Lupus Erythematosus (SLE), where IGHV4-34-encoded antibodies are highly enriched in the autoantibody repertoire and correlate with disease activity and lupus nephritis [13, 14, 15]. Additionally, this BCR is overrepresented in specific B-cell malignancies, including activated B-cell type diffuse large B-cell lymphoma (ABC-DLBCL) and primary central nervous system lymphoma, where BCR signaling supports tumor cell survival [1, 4, 19]. As a therapeutic target, the IGHV4-34 BCR is being investigated for precision medicine through the development of CAR-T cell therapies (such as CART4-34) and specialized monoclonal antibodies [1, 5, 7]. These therapies aim to selectively eliminate diseased clones by targeting the 9G4 idiotype, offering a strategy to treat B-cell disorders while avoiding the broad immunosuppression associated with pan-B-cell depleting agents like anti-CD19 or anti-CD20 [3, 6, 7].

Other names

VH4-34 B-cell receptorV4-34 B-cell receptor9G4-positive B-cell receptorIGHV4-34 gene product9G4 idiotype

Selective depletion of pathogenic or malignant B-cell clones by targeting the unique 9G4 idiotype of the IGHV4-34-encoded B-cell receptor, thereby neutralizing autoantibody production and tumor survival while sparing the majority of the healthy B-cell repertoire.